部裂:关于治疗选择的最新情况
Veronica Lyle1, Christopher J Young2
1BSc, University of Kansas School of Medicine, Salina, KS, USA.
Australian journal of general practice
|February 5, 2024
概括
门裂 (AF) 是常见的门疾病,引起严重的疼痛. 治疗范围从饮食和坐浴等保守措施到局部药物或持续病例的手术.
科学领域:
- 胃肠病学 胃肠病学
- 结肠直肠手术 结肠直肠手术
背景情况:
- 门裂 (AF) 是一个常见的门状况.
- 在排便期间和之后的强烈疼痛的特征.
- 急性和慢性表现需要定制管理.
研究的目的:
- 审查裂的病理生理学.
- 详细说明AF的临床表现.
- 概述AF目前的管理准则.
主要方法:
- 裂病理生理学的文献综述.
- 临床表现的分析.
- 目前治疗指南的综合.
主要成果:
- AF病因通常不清楚,与创伤或慢性疾病有关.
- 保守治疗 (饮食,坐浴) 是急性AF的第一线治疗.
- 局部酸盐,CCB或肉毒毒素是耐火病例的选择.
结论:
- 外科干预只适用于持续性AF.
- 大多数AF病例是高压的,需要对低压或二次类型进行特殊考虑.
- 综合管理涉及了解AF亚型和治疗升级.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
147
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
147
Peptic Ulcer Disease IV: Management
93
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
93
Drugs for Treatment of Constipation-Predominant IBS
169
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
169
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Diarrhea-Predominant IBS
175
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
175
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141


